Myeloma Paper of the Day, August 20th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Global study of 61,725 patients with newly diagnosed myeloma undergoing upfront AHCT from 9 national/international registries shows median OS 90.2 months & PFS 36.5 months with non-relapse mortality of 1%-3%.”
Authors: Laurent Garderet, Luuk Gras, Linda Koster, Laurien Baaij, Nada Hamad, Anita Dsouza, Noel Estrada-Merly, Parameswaran Hari, Wael Saber, Andrew J Cowan, Minako Iida, Shinichiro Okamoto, Hiroyuki Takamatsu, Shohei Mizuno, Koji Kawamura, Yoshihisa Kodera, Bor-Sheng Ko, Christopher Liam, Kim Wah Ho, A Sim Goh, S Keat Tan, Alaa M Elhaddad, Ali Bazarbachi, Qamar Un Nisa Chaudhry, Rozan Alfar, Mohamed-Amine Bekadja, Malek Benakli, Cristobal Augusto Frutos Ortiz, Eloisa Riva, Sebastian Galeano, Francisca Bass, Hira S Mian, Arleigh McCurdy, Feng Rong Wang, Ly Meng, Daniel Neumann, Mickey Koh, John A Snowden, Stefan Schönland, Donal P McLornan, Patrick John Hayden, Anna Sureda, Hildegard T Greinix, Mahmoud Aljurf Yoshiko Atsuta, and Dietger Niederwieser.
Source: Robert Orlowski/X
Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.
